Riskpilot← Back to searchSign inGet full accessCureMed Nordic AB
ABActiveOrg 5590747068Gruvgatan 35 AWholesale of pharmaceutical and medical goods · NACE 4646Est. 20160 employees
Revenue 2024
SEK 9,4M
+24% vs 2023
EBITDA margin
-5.6%
-188% vs 2023
Equity ratio
29.7%
Financial strength
Net profit 2024
SEK -577K
-119% vs 2023
| Revenue | SEK 9,4M | +24% |
| EBITDA | SEK -525K | -188% |
| Net profit | SEK -577K | -119% |
| Total assets | SEK 3,6M | +5% |
| Equity | SEK 1,1M | +19% |
| Employees | 0 | — |
Legal name
CureMed Nordic AB
Org number
5590747068
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1 september 2016
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolagets verksamhet ska vara att bedriva försäljning av medicintekniska produkter samt därmed förenlig verksamhet.
Address
Gruvgatan 35 A
Email
info@curemednordic.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 5 757 | 8 815 | 8 612 | 7 528 | 9 368 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −1 632 | −1 020 | −67 | −182 | −525 |
| Depreciation & amort. | −54 | −66 | −64 | −60 | −34 |
| EBIT | −1 686 | −1 086 | −131 | −242 | −559 |
| Net financials | −26 | −22 | −19 | −21 | −18 |
| Profit before tax | −1 712 | −1 108 | −151 | −263 | −577 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −1 712 | −1 108 | −151 | −263 | −577 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 332 | 1 721 | 4 110 | 3 423 | 3 581 |
| Equity | 51 | 51 | 52 | 889 | 1 062 |
| Long-term debt | 46 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 234 | 1 670 | 4 058 | 2 534 | 2 519 |
| Total debt | 2 280 | 1 670 | 4 058 | 2 534 | 2 519 |
EBITDA margin
-5.6%
This company
15.8%
Market median
-135% vs market
20202024
Equity ratio
29.7%
This company
38.2%
Market median
-22% vs market
20202024
Return on equity
-54.3%
This company
18.4%
Market median
-395% vs market
20202024
Net profit margin
-6.2%
This company
8.1%
Market median
-177% vs market
20202024
Asset turnover
2.62×
This company
1.12×
Market median
+134% vs market
20202024
Debt / equity
2.37×
This company
0.62×
Market median
-282% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AP Chief Executive Officer | Chief Executive Officer | 2024 |
UT Audit | Audit | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2021 | |
| Board of Directors | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CureMed Nordic AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Arne Puhasmägi | Chief Executive Officer | 0 companies |
| Ulf Thomas Andresen | Audit | 0 companies |
| Eva Ann-Christine Puhasmägi | Deputy Board Member | 0 companies |
| Erik Anders Petersén | Board of Directors | 0 companies |